Quick answer
Stem cells do not yet cure any neurodegenerative disease, and no stem cell therapy is approved for Alzheimer’s, Parkinson’s, ALS or Huntington’s disease. The most promising results so far are small early trials: a 12-patient Parkinson’s study of lab-grown dopamine neurons found the cells survived and were safe, a 49-patient Alzheimer’s study of mesenchymal cells slowed brain shrinkage, and in multiple sclerosis a stem cell transplant beat standard drugs in a randomized trial. Large trials, such as the phase 3 ALS study, have so far missed their main goals. Stem cells are best viewed as promising research, not a replacement for standard care.
Key facts at a glance
- Parkinson’s disease: early trials of lab-grown dopamine neurons show safety and graft survival; efficacy is not yet proven.
- Alzheimer’s disease: a phase 2a mesenchymal cell trial slowed brain atrophy and was safe; it is small and not yet confirmed.
- ALS: the largest phase 3 mesenchymal cell trial (189 patients) did not slow decline significantly.
- Multiple sclerosis: autologous blood stem cell transplant reduced relapses and disability progression in a randomized trial, with real transplant risks.
- Unproven clinics: treatments sold outside regulated trials may be unsafe and can cost patients money without helping.
What are neurodegenerative diseases, and why are they so hard to treat?
Neurodegenerative diseases are conditions in which nerve cells (neurons) gradually lose function and die, so symptoms steadily worsen over years. The main examples are Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS, also called motor neuron disease), Huntington’s disease and multiple sclerosis (MS), which differs because the immune system damages the nerve coating.
Why is it hard to repair the brain and spinal cord?
- Lost neurons do not regrow well. Adult brains have very limited ability to replace the specific neurons that die.
- Different diseases attack different cells. Parkinson’s mainly loses dopamine neurons, ALS loses motor neurons and Alzheimer’s affects memory networks, so one cell type cannot fix all of them.
- The damage is spread out. In Alzheimer’s and ALS many regions are involved, which makes replacing cells much harder than in Parkinson’s, where the loss is concentrated.
- The blood-brain barrier limits delivery. Many drugs and cells cannot easily enter the brain from the blood, so cells are sometimes injected directly into the brain or spinal fluid.
- The cause is often still active. If misfolded proteins or immune attack continue, new cells can be damaged too.
For Viezec’s own explainers on these diseases, see the neurological conditions hub, how stem cells can be used in neurological disorders, Parkinson’s disease stem cell treatment, Alzheimer’s stem cell treatment, motor neuron disease and multiple sclerosis.
What does standard treatment offer today?
Standard treatment for neurodegenerative diseases mostly relieves symptoms or modestly slows decline; it rarely stops the disease. Knowing this baseline is essential for judging any stem cell claim.
| Disease | What standard care does | What it does not do |
|---|---|---|
| Alzheimer’s disease | Anti-amyloid antibodies lecanemab (Leqembi) and donanemab (Kisunla) slowed decline by about 27% and 36% to 60% in trials of early disease (Norton Healthcare) | They do not stop or reverse memory loss; brain swelling or bleeding (ARIA) occurred in about 21% (lecanemab) and 37% (donanemab) of trial patients |
| Parkinson’s disease | Levodopa-carbidopa is the most effective treatment; other medicines and deep brain stimulation help symptoms (Health in Aging) | There is no cure, and after 5 years about half of patients find medicines less effective or develop dyskinesia |
| ALS | Riluzole gives a two- to three-month survival benefit in pivotal trials; edaravone and, for SOD1-related ALS, tofersen are also approved (ALS TDI) | None reverses weakness; the tofersen phase 3 missed its main functional endpoint |
| Huntington’s disease | Medicines manage movement and mood symptoms; the gene therapy AMT-130 is experimental | No approved treatment slows the disease; AMT-130’s reported 75% slowing at 3 years is preliminary and not peer-reviewed (Powers Health) |
| Multiple sclerosis | Disease-modifying drugs reduce relapses and slow disability; rehabilitation and symptom care support daily life | Progressive forms respond less well to drugs |
Everything above comes with rehabilitation, nutrition and caregiver support, which are part of good care. Viezec shares practical guidance in diet tips for Parkinson’s patients, diet tips for Alzheimer’s patients, multiple sclerosis self-care and treatments for Parkinson’s.
How might stem cells help in neurodegenerative disease?
Stem cells are being studied in three different ways: replacing lost neurons, protecting the neurons that remain, and calming harmful immune activity. Which of these a trial is testing matters, because they carry very different levels of ambition and evidence.
1. Cell replacement
Lab-grown cells, usually made from embryonic or induced pluripotent stem cells, are turned into the specific cell type that is lost and transplanted into the brain. This works best where one cell type is concentrated in one area, as with dopamine neurons in Parkinson’s disease. See Viezec’s explainers on induced pluripotent stem cells and neural stem cells.
2. Support and protection (the paracrine effect)
Mesenchymal stem cells (MSCs) from bone marrow, umbilical cord or fat are not expected to become neurons. The leading idea is that they release growth factors and anti-inflammatory signals that may help surviving neurons. This is a proposed mechanism and has not been shown to translate into lasting benefit in large trials. Read how mesenchymal stem cells really work and whether MSCs cross the blood-brain barrier.
3. Immune reset
In multiple sclerosis, the aim is to wipe out the faulty immune system with chemotherapy and rebuild it with the patient’s own blood stem cells (autologous hematopoietic stem cell transplantation, or AHSCT). The stem cells here rebuild the immune system; they do not replace nerve cells. See hematopoietic stem cells transplantation and autologous hematopoietic stem cell transplantation benefits.
How are the cells delivered?
- Into the brain by surgery (Parkinson’s cell transplants), which gives the most precise delivery but carries surgical risk.
- Into the spinal fluid (intrathecal), used in ALS trials, to reach the brain and spinal cord more directly than the bloodstream.
- By intravenous infusion (Alzheimer’s MSC trials, MS transplant), which is easier but delivers fewer cells to the brain.
Viezec’s page on the delivery method explains the options in simple terms.
What does the evidence show, disease by disease?
The evidence is strongest for multiple sclerosis, early but encouraging for Parkinson’s and Alzheimer’s, and disappointing so far for ALS. Here is what each key study found.
Parkinson's disease: lab-grown dopamine neurons
In an open-label phase I trial of bemdaneprocel, 12 patients received human embryonic stem cell-derived dopamine neurons grafted into the putamen, 5 at a low dose (0.9 million cells) and 7 at a high dose (2.7 million cells), with one year of immunosuppression. The study met its safety goal, with no adverse events related to the cell product and no graft-induced dyskinesias. Brain scans at 18 months showed rising dopamine-related uptake, interpreted as graft survival, and the high-dose group’s OFF-medication motor score improved by an average of 23 points (trial summary). Because all patients kept taking levodopa and there was no control group, the researchers stress that it is unclear whether the cells caused the gains (UHN).
Alzheimer's disease: mesenchymal cells
The CLEARMIND phase 2a trial randomized 49 adults aged 60 to 85 with mild Alzheimer’s to placebo or one of three regimens of the bone marrow-derived cell product Lomecel-B. Across the treated groups, whole-brain volume declined 48% more slowly and hippocampal volume 59% more slowly than with placebo at 39 weeks, with no excess serious adverse events and no ARIA. Cognitive results were mixed between groups. The study was small, short, and supported by the product’s developer (Practical Neurology).
ALS: a large trial that missed its goal
The phase 3 trial of NurOwn, a mesenchymal cell product, enrolled 189 patients with rapidly progressing ALS. At 28 weeks, 34.7% on NurOwn met the main endpoint (at least 1.25 points slower decline on the ALSFRS-R scale) versus 27.7% on placebo, a difference that was not statistically significant. A pre-specified subgroup with less advanced disease looked better (34.6% vs 15.6%), but that was not statistically significant either (ALS News Today, 2020).
Multiple sclerosis: blood stem cell transplant
In the MIST trial, 110 patients with relapsing MS were randomized to autologous stem cell transplant or standard disease-modifying drugs. After one year, 1 of 52 transplant patients (1.92%) relapsed versus 36 of 52 (64.3%) on drugs, and the transplant group’s disability score improved by an average of 1.02 points while the drug group worsened by 0.67. The comparison drugs did not include newer therapies such as ocrelizumab, so the relative benefit against today’s best drugs is less clear (MSIF). A newer US trial, BEAT-MS, compares the transplant with best available therapy; I have only seen its registry listing, so check its published results before quoting it (ClinicalTrials.gov).
For Viezec’s own pages, see stem cell treatment for multiple sclerosis, stem cell treatment for Parkinson’s, stem cell treatment for Alzheimer’s, stem cell treatment for ALS and stem cell clinical trial results.
What are the realities patients and families should know?
The honest reality is that stem cell therapy for neurodegenerative disease is still experimental, and the gap between research results and clinic marketing is large. Five points deserve attention.
- Nothing is approved for these diseases. The US FDA lists only a small number of approved stem cell-based products, none of them for neurodegenerative disease, and warns that stem cell and exosome products offered outside a regulated trial may be unapproved, deceptive and unsafe (FDA). Rules in other countries differ, so ask any clinic how it is regulated.
- Early results are not proof. The Parkinson’s and Alzheimer’s trials above were small and early, and the ALS phase 3 missed its goal. Positive subgroups and brain scans are hints, not cures.
- Transplants carry real risks. Reported or possible harms include infection, bleeding, immune reactions, unwanted tissue growth and, for the MS transplant, chemotherapy complications. The FDA lists tumour formation and neurological events among harms from unapproved products.
- Marketing runs ahead of the science. The Michael J. Fox Foundation notes that clinic testimonials are “far ahead of the science,” that cell sources and delivery routes vary widely, and that peer-reviewed safety and outcome data are generally missing. It advises “extreme caution and skepticism” outside recognised trials (Michael J. Fox Foundation).
- Cells may not fix every symptom. Replacing dopamine cells would likely help movement symptoms, but may not help non-motor symptoms or freezing in Parkinson’s (Michael J. Fox Foundation).
What does this mean for expectations?
The realistic goals today are to slow decline, protect function and quality of life, and contribute to research, not to reverse the disease. Any provider who promises more should be questioned.
Read Viezec’s pages on safety and adverse effects of stem cell treatment, stem cell therapy safety, limits of stem cell therapy and myths and facts about stem cell therapies.
Stem cells and neurodegenerative diseases: side-by-side summary
This table shows, for each disease, the strongest stem cell evidence and how far it is from routine use.
| Disease | Cell approach studied | Strongest result so far | Evidence level | Main caution |
|---|---|---|---|---|
| Parkinson’s disease | Embryonic stem cell-derived dopamine neurons grafted into the brain | 12 patients: safe, graft survival on scans, 23-point OFF motor score gain in the high-dose group | Phase I, open-label; phase 3 planned | No control group; patients stayed on levodopa; brain surgery and immunosuppression |
| Alzheimer’s disease | Bone marrow-derived mesenchymal cells (Lomecel-B), intravenous | 49 patients: brain volume loss 48% slower than placebo at 39 weeks | Phase 2a, randomized | Small and short; cognitive results mixed; developer-funded |
| ALS | Mesenchymal cells (NurOwn) | 189 patients: 34.7% vs 27.7% responders, not significant | Phase 3, missed main goal | Subgroup signal was not significant; no proven benefit |
| Multiple sclerosis | Autologous blood stem cell transplant (immune reset) | 110 patients: relapse in 1.92% vs 64.3% after one year | Randomized trial | Chemotherapy risks; older comparison drugs; relapsing disease only |
| Huntington’s disease | No stem cell therapy approved; related gene therapy (AMT-130) is investigational | Reported 75% slowing at 3 years, preliminary | Early trial, not peer-reviewed | Gene therapy, not stem cells; surgical delivery |
Sources: trial summary, Practical Neurology, ALS News Today, MSIF and Powers Health.
Who might consider stem cell therapy, and what should come first?
Most people with a neurodegenerative disease are best served by proven care first, with stem cell options explored only through a regulated clinical trial or under specialist guidance. A neurologist who knows your diagnosis and stage should be part of every decision.
Who may reasonably look at cell therapy
- Patients with a confirmed diagnosis who want to understand research options and have discussed them with their own neurologist.
- People who meet the strict entry criteria of a registered clinical trial (stage, age, other medicines).
- Adults with relapsing multiple sclerosis that is active despite drugs, who may be assessed for an immune-reset transplant at an experienced centre.
What should always continue alongside
- Prescribed medicines and regular neurology review.
- Physiotherapy, occupational therapy and speech therapy.
- Nutrition, exercise, sleep and caregiver support.
Read Viezec’s guides on neuro-regenerative rehabilitation therapy, physiotherapy, occupational therapy and how to manage life after stem cell treatment.
How to evaluate a clinic offering neuro stem cell therapy
- Ask which cells are used, where they come from and how they are tested and given.
- Ask for the registered trial number or published study for your exact condition.
- Ask who the treating neurologist is and how you will be assessed before and after, with baseline scores.
- Ask for the written risks and what happens if something goes wrong.
- Be cautious about guaranteed results, treating many unrelated diseases with the same cells, or pressure to pay quickly.
To discuss your reports with a specialist, contact the Viezec team. International patients can start with the international patient flow chart and medical visa process.
Where is the field heading?
The next two years should show whether the early promise holds up in properly controlled trials. Four developments are worth watching.
- Parkinson’s phase 3: Bayer and BlueRock planned a randomized, double-blind, sham-surgery-controlled phase 3 trial of bemdaneprocel in about 102 people with moderate Parkinson’s disease. Its main endpoint is change in “good ON-time” (hours of movement control without troublesome dyskinesia) at 78 weeks (Bayer). That page described the trial as planned, so check its current status.
- Huntington’s gene therapy: uniQure said in July 2026 that it expected to file for accelerated approval of AMT-130 in the third quarter of 2026, after the FDA agreed that a filing based on existing data was “reasonable”, with the risk that the FDA could still find the data insufficient (uniQure, 29 July 2026). This is gene therapy, not stem cells, but it will shape how regulators judge brain therapies.
- Alzheimer’s cell therapy: the next step after the CLEARMIND phase 2a trial is larger, longer trials to test whether slower brain shrinkage translates into better memory and daily function.
- MS transplant versus modern drugs: the BEAT-MS trial is designed to compare the transplant with the best available drugs (ClinicalTrials.gov).
Until those results arrive, treat each headline as one data point. Viezec’s advances in mesenchymal stem cell therapy for neural and retinal disorders and how mesenchymal stem cell therapy could revolutionize Parkinson’s management give longer background.
Frequently asked questions
No. No stem cell treatment has been shown to cure any neurodegenerative disease. Early trials, such as the phase I bemdaneprocel study in Parkinson’s and the CLEARMIND phase 2a study in Alzheimer’s, report safety and encouraging signals, but they are small and mostly early-stage. In ALS, the largest stem cell trial (NurOwn, phase 3) did not meet its main goal.
Not as a routine treatment. As far as the sources reviewed show, stem cell products for these conditions are still being tested in clinical trials. Check the current FDA and CDSCO status before any decision, because this field changes quickly.
A trial has a registered protocol, ethics approval, defined entry criteria and monitored outcomes, and is usually free or covered by the sponsor. A clinic offering an unproven treatment for a fee often has none of these. Ask for the trial registration number and the ethics committee approval.
Mainly two types: mesenchymal stromal cells (from bone marrow, fat or umbilical cord), studied for their possible anti-inflammatory and supportive effects, and pluripotent-derived cells (such as dopamine-producing neurons for Parkinson’s), studied as replacement cells.
Yes. Possible risks include infection, reactions to the procedure, immune reactions, and, with poorly controlled products, abnormal cell growth. Procedures that go into the spine or brain carry added surgical risk. Discuss these with a neurologist first.
No. In the Parkinson’s trial, participants continued levodopa. Do not stop or change prescribed treatment without your neurologist’s advice.
People who meet a specific trial’s criteria, usually a defined diagnosis, stage and age range and a stable medical condition. Your neurologist can check registries such as ClinicalTrials.gov and the Clinical Trials Registry of India.
Look for a control group, a published peer-reviewed result, a pre-defined main outcome and a long enough follow-up. Testimonials and before-and-after videos are not evidence.
Conditions We Treat
Explore stem cell treatment options in India
















